43 annotations
Page 2 of 3
SMB, which is roughly 40% of the total pharma
(No comment added)
Transcript
2023 Q2
2 Sep 22
pharma represents about 90% of Veeva’s overall revenue with the balance being med tech and CPMC. And we think enterprise customers represent roughly 60% of our total pharma revenue and we define enterprise as the top 50 or so largest pharma companies.
(No comment added)
Transcript
2023 Q2
2 Sep 22
if you unpack the reduction, about half of the reduction is related to FX as the dollar continued to strengthen over the last 90 days.
The other half relates to the overall macro dynamics.
(No comment added)
Transcript
2023 Q2
2 Sep 22
if you take a look at the reduction, half of it is FX related
(No comment added)
Transcript
2023 Q2
2 Sep 22
We have revised our full year revenue guidance down by about 1.5% at the top end from $2.175 billion to $2.145 billion due to foreign currency and macroeconomic factors.
(No comment added)
Transcript
2023 Q2
2 Sep 22
the quarter started out a little bit more typical and then we started to see that later in the month of June.
(No comment added)
Transcript
2023 Q2
2 Sep 22
we started to see some of the impact in the later part of June.
(No comment added)
Transcript
2023 Q2
2 Sep 22
that was where we started to see a little bit of the headwinds from a lower spend in SMBs and a little bit of additional deal scrutiny.
(No comment added)
Transcript
2023 Q2
2 Sep 22
we talked about lower spending in SMBs, and that’s more in the lower half of that SMB definition that I was describing before because that SMB space is a very wide space
(No comment added)
Transcript
2023 Q2
2 Sep 22
We’ve factored in that there is some increased deal scrutiny and also some lower spend in SMBs.
(No comment added)
Transcript
2023 Q2
2 Sep 22
we have also saw little bit of lower add-on users from SMB customers in the CRM and Vault Commercial
(No comment added)
Transcript
2023 Q2
1 Sep 22
advertising budgets have tightened a bit.
(No comment added)
Transcript
2023 Q2
1 Sep 22
as far as the lower spending in SMB, that is more pronounced on the lower end and on the commercial side.
(No comment added)
Transcript
2023 Q2
1 Sep 22
Please note that our total revenues and subscription services revenues for our fiscal year ended January 31, 2020 only included revenue contribution from the acquired Crossix and Physicians World businesses in the fourth quarter of that fiscal year.
(No comment added)
10-Q
2022 Q1
1 Sep 22
And then you can kind of split the other balance between Crossix, which you called out, there was a little bit more pronounced impact to the Crossix business and then the balance would be more broadly
(No comment added)
Transcript
2023 Q2
1 Sep 22
they will follow the amount of advertising spend the customer does in general
(No comment added)
Transcript
2023 Q2
1 Sep 22
people spend a little bit less in advertising and so that flows through to Crossix
(No comment added)
Transcript
2023 Q2
1 Sep 22
how are your advertising going and some of it is more programmatic, which is you can buy audience for us – from us, patient audiences
(No comment added)
Transcript
2023 Q2
1 Sep 22
We have seen some impact to Crossix as advertising budgets have tightened a bit.
(No comment added)
Transcript
2023 Q2
1 Sep 22
Veeva Crossix provides analytics derived from de-identified third-party health and consumer data on U.S. residents that life sciences companies use for measurement of their advertising objectives.
(No comment added)
10-Q
2022 Q1
1 Sep 22